There is a tremendous amount of noise surrounding GLP-1 medications right now. Depending on who is speaking, they are either the miracle answer to America’s obesity crisis or a dangerous shortcut for people who supposedly do not want to “do the work.”
Both arguments are overly simplistic, and frankly, both are lazy.
GLP-1 receptor agonists such as semaglutide, along with dual GIP/GLP-1 medications such as tirzepatide, can produce meaningful weight loss, improve glucose regulation, reduce cardiovascular risk and significantly change a person’s quality of life. For some patients, these medications have been nothing short of life-changing.
That deserves to be acknowledged without shame, stigma or the moral judgment we continue to attach to body size.
At the same time, helping individual patients lose weight does not mean we have solved America’s obesity crisis. We have not. The medications are working for many people, yet the crisis remains.
The more important question is not whether GLP-1 medications are good or bad. The real question is WHY such a large percentage of the American population now requires medication to protect itself from the environment and systems in which we are asking people to live.
That is where the real conversation begins.
The clinical benefits are real.
In the STEP 1 trial, adults with overweight or obesity who received semaglutide lost an average of 14.9% of their starting body weight over 68 weeks, compared with 2.4% in the placebo group. In the SURMOUNT-1 trial, tirzepatide produced average weight reductions of approximately 15% to 20.9% over 72 weeks, depending on the dose.
For a person weighing 250 pounds, that may represent a loss of 37 to 50 pounds. That can mean less pressure on painful joints, better mobility, improved glucose regulation, lower blood pressure, reduced sleep apnea and a better quality of life.
The benefits also extend beyond the scale. In the SELECT cardiovascular outcomes trial, semaglutide reduced the risk of major adverse cardiovascular events by 20% among adults with overweight or obesity and established cardiovascular disease who did not have diabetes.
A medication that can reduce the risk of heart attack, stroke and cardiovascular death is not simply a vanity drug. It is medicine.
For the right person, prescribed for the right reasons and managed appropriately, these medications may reduce food noise, improve metabolic health and create the breathing room needed to participate more fully in nutrition, movement and other health changes.
Those benefits are real. They should not be diminished.
Individual success is not the same as population progress
The national numbers tell a more complicated story.
The latest measured data from the CDC’s National Health and Nutrition Examination Survey cover August 2021 through August 2023. During that period, 40.3% of American adults had obesity, 9.7% had severe obesity and another 31.7% were categorized as overweight.
That means approximately seven out of every ten American adults suffer from overweight or obesity.
Among children and adolescents ages 2 through 19, 21.1% had obesity, including 7% living with severe obesity.
One in five American children are already living with obesity.
We can continue to frame this as a personal responsibility problem, but at some point the numbers become far too large for that explanation to remain credible. When seven out of ten adults are affected, we are not talking about a handful of people possibly making poor choices. We are looking at systems producing predictable results.
There was an apparent decline in adult obesity prevalence from 41.9% during 2017 through early 2020 to 40.3% during 2021 through 2023. However, that difference was not considered statistically significant. Over the longer term, severe obesity actually increased from 7.7% to 9.7%.
That is not a victory.
Semaglutide prescribing has expanded dramatically. Retail prescription fills increased approximately 442% between January 2021 and December 2023, rising from roughly 472,000 to more than 2.5 million monthly fills.
However, the most recent nationally measured obesity data end in August 2023. They capture only the earliest years of widespread Wegovy use and barely touch the period following the introduction of tirzepatide for obesity treatment. And we have little data around the increase use of compounded GLP1/GIP useage.
The honest answer is that we do not yet have enough mature national data to say that GLP-1 medications have reduced America’s obesity rate.
That does not mean the medications are failing. It means individual treatment success and population-level progress are not the same thing.
Both truths can exist at the same time.
The gut conversation needs facts, not dismissal or fear
GLP-1 and GIP/GLP-1 medications affect the gastrointestinal system because that is part of how they work. They slow gastric emptying, alter appetite signaling, increase satiety and change how quickly food moves through the digestive tract.
In adult Wegovy trials, 73% of patients reported gastrointestinal adverse reactions, compared with 47% receiving placebo. Nausea occurred in 44%, diarrhea in 30%, vomiting in approximately 24% and constipation in 24%.
In pooled Zepbound weight-management trials, gastrointestinal reactions occurred in approximately 56% of patients, compared with 30% receiving placebo. Nausea occurred in 25% to 29%, diarrhea in 19% to 23%, vomiting in 8% to 13% and constipation in 11% to 17%.
Most symptoms were mild to moderate and occurred during dose escalation. But “common and usually temporary” does not mean clinically irrelevant.
A patient who is persistently nauseated, dehydrated, barely eating, losing muscle and unable to move their bowels is not experiencing optimized health. They are experiencing poorly managed treatment with adverse drug reactions.
Patients should not be handed a prescription, told to eat less and scheduled to return three months later. That is not comprehensive obesity care. That is dispensing medication and hoping for the best.
Gallbladder and biliary disease represent one of the clearer established risks. In Wegovy trials, gallstones occurred in 1.6% of treated patients compared with 0.7% receiving placebo, while cholecystitis occurred in 0.6% compared with 0.2%. Rapid weight loss itself also increases gallstone risk, so both the medication and the speed of weight loss may contribute.
Reflux also appears to be modestly increased. More serious concerns, including gastroparesis, ileus, bowel obstruction, severe constipation and fecal impaction, have been reported. However, randomized trials have not consistently established a class-wide increase in many of these uncommon outcomes.
A safety signal is not the same as confirmed causation. The absence of definitive proof also does not give us permission to dismiss a patient whose gut is clearly telling us something is wrong.
At this time, diverticulitis is not an established adverse effect of GLP-1 or GIP/GLP-1 therapy. Case reports exist, often involving constipation or underlying diverticular disease, but case reports cannot establish incidence or prove causation.
The most responsible conclusion is that these medications commonly cause constipation and alter gastrointestinal motility. Those effects could plausibly worsen symptoms or contribute to complications in a susceptible patient, particularly someone with severe constipation, dehydration, previous obstruction or significant diverticular disease.
A direct causal relationship between GLP-1 use and diverticulitis has not been established.
That is the real data. Not clickbait. Not fearmongering. Not blind reassurance.
These medications also require a longer-term conversation. Weight regain after discontinuation is common, as demonstrated in both semaglutide and tirzepatide withdrawal studies.
That does not prove the medications failed. Blood pressure often rises when antihypertensive medication is stopped. Glucose often rises when diabetes treatment ends. Obesity is also a chronic, relapsing disease influenced by neuroendocrine signaling, metabolic adaptation, genetics, hormones, environment and behavior.
For many patients, long-term treatment may be appropriate. But that raises some very practical questions: Who can afford it? Who receives insurance coverage? Who gets competent nutrition support? Who is monitoring hydration, bowel function, protein intake, muscle mass and bone health? Who is monitoring the mental health around weight, food habits, and self image?
In a 2025 KFF survey, 56% of people who had used GLP-1 medications said they were difficult to afford. Cost and side effects were among the most common reasons people stopped treatment.
A medication cannot transform population health if the people who need it cannot access it, tolerate it, afford it or receive proper clinical support and guidance while taking it.
The question society keeps avoiding is why
Why are more than 40% of American adults living with obesity? Why has severe obesity continued to rise? Why does one in five American children already have obesity?
Why are we spending billions of dollars treating metabolic disease after it develops while continuing to protect the systems that help create it?
Ultra-processed foods are inexpensive, aggressively marketed and available nearly everywhere. Nutrient-dense foods remain financially or geographically inaccessible to many families. We tell people to move more while designing communities where walking is unsafe, inconvenient or practically impossible. We advise exhausted shift workers to get eight hours of sleep while ignoring the staffing shortages, work schedules and economic pressures that make adequate sleep unrealistic.
We reduce obesity to calories, discipline and willpower while minimizing the effects of trauma, chronic stress, endocrine disruption, medication exposure, poverty, food insecurity, social isolation and generational patterns of illness.
We often wait until someone develops diabetes, hypertension, fatty liver disease, sleep apnea and joint damage before insurance agrees that meaningful intervention is medically necessary. Nutrition services, exercise support and preventive metabolic care are treated as optional, while dialysis, cardiac procedures and joint replacements are funded after years of progressive disease.
Then we blame individuals for developing the very conditions our systems are structured to produce.
That is the part of this conversation we need to stop sugar-coating.
Pun fully intended.
GLP-1 medications are part of the answer, not the whole damn answer
GLP-1 and GIP/GLP-1 therapies are among the most important advances in metabolic medicine in decades. They deserve appropriate use, thoughtful insurance coverage and conversations free from shame.
They also require real clinical oversight.
Patients need appropriate screening, individualized dose escalation, hydration planning, bowel support, adequate nutrition, resistance training and strategies to preserve lean muscle and bone. They need clinicians who ask how they feel, what they are eating, whether they are moving their bowels and whether treatment is improving their actual health.
A smaller body is not automatically a healthier body.
Even the best-prescribed medication cannot repair a broken food system. It cannot create safe neighborhoods, eliminate poverty, restore sleep to an exhausted workforce or guarantee access to preventive care. It cannot correct medical mistrust or erase decades of weight bias and dismissal.
A GLP-1 medication may help one person’s biology function more effectively. Society’s responsibility is to ask why the biology of millions of people is being pushed beyond its limits in the first place.
We do not need to choose between supporting these medications and demanding systemic change. That is a false choice. We need both.
We need medication when it is clinically appropriate, but we also need real nutrition rather than diet-culture nonsense. We need movement that builds strength, mobility and longevity. We need adequate sleep, affordable food, preventive healthcare and better health literacy. We need clinicians who have the time and training to look beyond body weight and understand the entire person.
We also need accountability from healthcare systems, insurers, policymakers, employers and the industries shaping what people eat, how they work and how they live.
The goal cannot simply be to help more Americans qualify for a prescription. The goal must be to create a society in which fewer people become metabolically sick in the first place.
GLP-1 medications may help us treat the fire. But unless we are willing to ask who keeps handing out the matches, we will be writing prescriptions forever.
That is the bigger picture. That is the uncomfortable truth. And that’s the Power-of-One Conversation.
Frequently Asked Questions About GLP-1 Medications
GLP-1 medications can produce meaningful weight loss, improve glucose regulation, reduce cardiovascular risk and significantly improve a person’s quality of life. They may also reduce food noise, improve metabolic health and help patients participate more fully in nutrition, movement and other health changes.
Common gastrointestinal side effects include nausea, diarrhea, vomiting and constipation. These medications slow gastric emptying, alter appetite signaling, increase satiety and change how quickly food moves through the digestive tract. Most symptoms are mild to moderate and occur during dose escalation, but persistent nausea, dehydration, severe constipation or difficulty eating should not be dismissed.
We do not yet have enough mature national data to conclude that GLP-1 medications have reduced America’s obesity rate. The medications are working for many individuals, but individual treatment success and population-level progress are not the same thing. Both truths can exist at the same time.
